NEW YORK, March 28, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California, Western Division on behalf of investors who purchased Performance Sports Group Ltd. (NYSE:PSG) securities between August 27, 2015 and March 7, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/performance-sports-group. There is no cost or obligation to you.
The lawsuit concerns allegations that the Company and its executives violated federal securities laws by failing to disclose the financial pressures on the Company due to Sports Authority’s financial decline and the fall in demand in the softball, baseball and hockey markets.
If you suffered a loss in Performance Sports you have until May 17, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/performance-sports-group.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]


Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 



